Federal Containment Level 2 license will support testing and validation for studies and sale of natural products VANCOUVER, BC, March 14, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its research lab…

Source

Previous articlePsychedelic Bulletin: Tensions Rise among Oregon’s Psilocybin Advisory Board; Colleges Team up to Develop Psychedelic Curriculum
Next articleRed Light Holland and Advocacy Group Psychedelic Medicine Alliance Washington Celebrate the Success of their Collaboration as Washington Legislature Funds Psilocybin Wellness Workgroup